Lilly investing up to $150M in VC funds
The three venture funds, which will focus on drug development, may be worth a total of $750 million, up to $250 million each, and Lilly will contribute as much as 20 percent of the money.
Eli Lilly and Co.
Articles
CEO says Lilly still not interested in huge acquisitions
Lilly remains disinterested in making big acquisitions and aims to rely on the company’s own pipeline, CEO John Lechleiter said Tuesday, re-emphasizing a strategy he has outlined several times in the past year.
Appeals court ruling upholds Lilly’s Evista patents
Eli Lilly and Co. won a court ruling Wednesday that blocks plans by Teva Pharmaceutical Industries Ltd. to sell a generic version of the Evista osteoporosis treatment before March 2014.
Lilly wins ban of generic Strattera pending appeal
The U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday granted Lilly’s request to prevent sales until the court rules on a judge’s decision invalidating a patent on the medicine.
After health reform, Lilly looking for more
The health reform debate may have ended in Congress, but Eli Lilly and Co. remains active, sponsoring a talk about the positives of the
bill—and calling for further government efforts to help pharmaceutical research and development.
Lilly wins further delay in sales of Strattera copies
Strattera generated U.S. sales of $445.6 million last year, and each day that Lilly can fend off generic competition would
translate into an average $1.22 million in sales.
Diabetes research pioneer Kirtley dies at 96
Diabetics who control their disease with pills instead of frequent insulin injections can thank Dr. William R. Kirtley, a
groundbreaking Eli Lilly researcher.
A half-century later, Indiana Landmarks returns to roots
Bankrolled by yet another multimillionaire, the historic preservation group is preparing to move into a new headquarters
in Old Centrum, a former church now undergoing a big renovation.
Lilly woes take notch out of debt rating
Even with debt levels at Eli Lilly and Co. at paltry lows, a string of bad news finally forced Standard & Poor’s
to lower
its rating on the company’s senior unsecured debt. But the New York-based agency said it believes the Indianapolis-based
drugmaker will eventually break its string of bad luck on developing new products.
Lilly gains panel’s backing to expand Cymbalta use
Outside advisers to the Food and Drug Administration voted 8-6 Thursday in favor of a broader use of Cymbalta on the basis
of studies in lower back pain and osteoarthritis of the knee.
Lilly wins temporary ban on sales of Strattera copies
The invalidation of Lilly’s Strattera patent opened the door for as many as 10 companies to sell generic versions of the drug,
which generated U.S. sales of $445.6 million last year as a treatment for attention deficit hyperactivity disorder.
Lilly Alzheimer’s drug prospect only the latest to fail
A dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the
disease since 1906, have failed in mid- to late-stage testing since 2003.
Bad news piles up for Lilly
What a tough week for Lilly. On Aug. 12, a judge struck down the Indianapolis-based drugmaker’s U.S. patent on Strattera,
which might cost the company about $450 million in annual revenue. Then, five days later, Lilly halted clinical trials on
one
of its experimental Alzheimer’s medicines, because patients did worse on the drug than on a placebo.
Lilly’s Cymbalta helps chronic pain in U.S. review
Approval for the millions of Americans with chronic back or knee pain may add more than $500 million, or 16 percent, to Cymbalta’s
annual sales.
Lilly halts development of Alzheimer’s drug
Studies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical
giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through
2014.
Eli Lilly loses patent lawsuit for Strattera
Eli Lilly and Co. on Thursday lowered its revenue outlook for the year after it lost a patent lawsuit over its attention
deficit hyperactivity drug Strattera. The patent had been set to expire in May 2017. Lilly plans to appeal.
Lilly braces for plunge in profits
Indianapolis-based drugmaker Eli Lilly and Co. faces such an unprecedented string of patent expirations and an unheard-of
loss of revenue that it’s hard to picture what the company will look like in five years.
Life sciences panel pegs bright spots in Indiana
Leaders tackle issues ranging from research to cold storage to the future of Eli Lilly and Co.
For Lilly, it’s a big one that got away
An experimental medicine for hepatitis C that Lilly helped identify and develop is now on the cusp of market approval, with
analysts predicting as much as $2 billion in annual U.S. sales.
Court defeat lost in Lilly’s gloomy long-term outlook
Eli Lilly and Co.’s loss of a patent on one of its blockbuster drugs in court late last month received a collective yawn
from
investors, who have shunned the stock because of five looming patent expirations.